Curis Provides First Quarter 2024 Business Update [Yahoo! Finance]
Curis, Inc. (CRIS)
Last curis, inc. earnings: 11/1 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.curis.com
Company Research
Source: Yahoo! Finance
biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the first quarter ended March 31, 2024 Operational Highlights The Company will release a topline update of clinical data from the ongoing TakeAim Leukemia study of emavusertib monotherapy in patients with relapsed or refractory (R/R) Acute Myeloid Leukemia (AML), including separate readouts for the FLT3 mutation (mFLT3) and Splicing Factor mutation (mSF) cohorts, on Tuesday, May 14, 2024 , in connection with the publication of accepted abstracts for the 2024 European Hematology Association (EHA) Conference. "We are very pleased to have several opportunities to present additional patient data in R/R AML patients with a targeted mutation (mFLT3 or mSF), as well as progress updates for our R/R PCNSL and AML frontline triplet studies, at these prestigious oncology meetings," said James Dentzer , P
Show less
Read more
Impact Snapshot
Event Time:
CRIS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRIS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRIS alerts
High impacting Curis, Inc. news events
Weekly update
A roundup of the hottest topics
CRIS
News
- Curis, Inc. (NASDAQ: CRIS) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $26.00 price target on the stock.MarketBeat
- Curis, Inc. (NASDAQ: CRIS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.MarketBeat
- Curis, Inc. (NASDAQ: CRIS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Curis Announces Additional Data from TakeAim Leukemia Study [Yahoo! Finance]Yahoo! Finance
- Curis Announces Additional Data from TakeAim Leukemia StudyPR Newswire
CRIS
Earnings
- 5/7/24 - Miss
CRIS
Sec Filings
- 5/14/24 - Form 8-K
- 5/7/24 - Form 10-Q
- 5/7/24 - Form 8-K
- CRIS's page on the SEC website